Retatrutide Vial Labeling: Reading Every Field on the Listing

Retatrutide vial labeling is supplier-declared from top to bottom. No regulator has approved a product label for the compound: it is still in registrational testing, with the four-study TRIUMPH phase 3 program running once-weekly subcutaneous retatrutide against placebo in over 5800 participants (TRIUMPH trial design report, 2026). Nothing printed on a retatrutide listing is mandated, so each field carries only the weight of the document behind it. Nine fields are worth reading: compound and code, nominal mass, purity method, lot number, COA date, identity confirmation, fill format, storage, and the use statement.

Why Is Every Field on a Retatrutide Listing Supplier-Declared?

Retatrutide (LY3437943) activates the GIP, GLP-1, and glucagon receptors, and its dose-response behaviour was characterised in a phase 2, double-blind, placebo-controlled obesity trial of 338 adults randomised to weekly 1 mg, 4 mg, 8 mg, or 12 mg for 48 weeks, with least-squares mean weight change at the 24-week primary endpoint running from -7.2% in the 1 mg group to -17.5% in the 12 mg group versus -1.6% on placebo (phase 2 obesity trial, NEJM 2023). That is a clinical development record, not a marketing authorisation. Material sold for research use sits outside it entirely.

The consequence for reading a listing is specific. Two suppliers can both describe “10 mg retatrutide” accurately while having measured different things, at different times, against different batches. The fields do not fail because a supplier is careless; they fail because nothing forces the fields to mean the same thing across vendors. Every check below is therefore a check on the document, not on the wording.

What Should Each Field on a Retatrutide Listing State?

#	Field	What it should state	What resolves it
1	Compound and code	Retatrutide, with the research code LY3437943	The code matches the identifier used in the published trial literature
2	Nominal mass	mg of lyophilised powder per vial, commonly 10 mg or 20 mg	Read against net peptide content, never assumed equal to peptide mass
3	Purity	The method named (HPLC) plus the figure, with the chromatogram available	A bare percentage with no named method and no trace cannot be checked
4	Lot or batch	An alphanumeric lot printed on the vial itself	The lot on the vial matches the lot at the top of the COA
5	COA date	The analysis date for that specific lot	An undated COA, or one reused across lots, resolves nothing
6	Identity	Mass spectrometry: observed mass against theoretical mass	Both masses printed, with the deviation shown rather than described
7	Fill format	Lyophilised powder, diluent not included, fill and headspace described	Matches what arrives; headspace is a fill artefact, not a shortfall
8	Storage	Sealed-vial condition and post-reconstitution condition, stated separately	Two conditions, not one blended sentence covering both
9	Use statement	Research use only, with no dosing or administration instruction	Any administration instruction contradicts the compound’s investigational status

Table 1: The nine fields a retatrutide vial listing carries, what each should state, and the check that resolves it. The identifier LY3437943 is the research code used in the phase 2 obesity trial report (PubMed 37366315); no field here is mandated by a regulator, because retatrutide remains investigational (TRIUMPH, PubMed 41090431).

Field 4 is the load-bearing one. A lot number is the only entry on the label that ties the vial in front of you to a specific analytical document; purity, identity, and COA date all hang off it. A listing that publishes a purity figure without a lot has published a claim about a product line, not about a vial.

What Does the mg Figure on the Vial Actually Mean?

The mg figure is the nominal mass of lyophilised powder, which includes bound water and counter-ions left from synthesis alongside the peptide itself. That is why how net peptide content is calculated sits next to the labelled mass rather than replacing it: the two numbers answer different questions, and only one of them is printed on most vials.

The mg figure also does not describe a concentration until a diluent volume is chosen, and no listing chooses that for you. Worked through for a 10 mg vial:

• Concentration = vial mass ÷ diluent volume = 10 mg ÷ 2 mL = 5 mg/mL
• In micrograms: 5 mg/mL × 1000 = 5000 mcg/mL
• On a U-100 syringe, 1 mL = 100 units, so 1 unit = 0.01 mL = 5000 × 0.01 = 50 mcg
• A 0.5 mg draw = 0.5 ÷ 5 = 0.1 mL = 10 units, and 10 × 50 mcg = 500 mcg, which is the same 0.5 mg

The same arithmetic on a 20 mg vial with 2 mL gives 10 mg/mL, so one unit carries 100 mcg and the same 0.5 mg draw falls to 5 units. Nothing about that changes what the label says; it changes what the label implies, which is why choosing a reconstitution volume for a 10 mg vial is a separate decision from reading the vial. A general calculator such as peptcalc.com will reproduce these figures if you enter the same inputs.

How Do Listed Vial Strengths Compare With the Amounts Studied?

A vial strength is a packaging quantity. It maps onto nothing in the trial record by itself, and the arithmetic makes the mismatch visible.

Weekly amount in the phase 2 arms (mg)	10 mg vial contains (× that amount)	20 mg vial contains (× that amount)
1	10.0	20.0
4	2.5	5.0
8	1.25	2.5
12	0.83	1.67

Table 2: Vial mass divided by each weekly amount used in the phase 2 obesity trial arms (1, 4, 8, and 12 mg once weekly; PubMed 37366315), computed as vial mg ÷ arm mg. Vial strengths of 10 mg and 20 mg are the formats most commonly listed. The quotients describe packaging quantity only and are not administration guidance.

Read the bottom row: a 10 mg vial does not contain a whole multiple of the largest studied weekly amount at all. Suppliers pick vial sizes for lyophilisation and shipping economics, not to divide evenly into any published protocol. Treating the mg on the label as a dose unit is the single most common misreading of a retatrutide listing.

Which Fields Go Vague Most Often?

Sterility language is first. “Sterile filtered” describes a process step applied to a solution before lyophilisation and does not by itself certify the finished sealed vial, which is why what sterile filtered actually covers is worth separating from any sterility assurance claim.

COA dating is second. A specification sheet that carries a product name and a set of thresholds, with no lot and no analysis date, is a template. It will be identical for every vial the supplier ships, which is exactly the property a batch-specific document must not have.

Third is the split between packaging layers. Storage conditions, lot, and expiry frequently appear on the carton while the vial itself carries only a name and a mass, so the difference between the box and the vial determines what remains identifiable once the carton is discarded. A vial with no lot printed on the glass becomes anonymous the moment it is separated from its box.

What the Label Cannot Tell You

No field on a retatrutide vial resolves potency. Purity by HPLC describes the proportion of correct sequence within the peptide fraction, mass spectrometry confirms identity, and net peptide content describes how much of the powder is peptide, but none of the three measures biological activity, and no listing has a field for it. The compound’s activity profile exists only in the trial literature, where it is measured in enrolled participants over defined periods rather than in a vial.

The practical request that gets past the label, for research-use material, is the raw chromatogram and mass spectrum for the specific lot number printed on the glass, dated. A supplier that can produce those two documents on a lot basis has given you something checkable; a supplier that answers with a specification sheet has restated the listing.